Leerink Partnrs Brokers Cut Earnings Estimates for Certara

Certara, Inc. (NASDAQ:CERT - Free Report) - Research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for shares of Certara in a note issued to investors on Sunday, November 17th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $0.32 per share for the year, down from their previous forecast of $0.33. The consensus estimate for Certara's current full-year earnings is $0.28 per share. Leerink Partnrs also issued estimates for Certara's FY2027 earnings at $0.40 EPS.

Other equities analysts have also issued research reports about the company. Robert W. Baird decreased their target price on Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a research note on Tuesday, November 5th. UBS Group raised Certara from a "neutral" rating to a "buy" rating and set a $16.00 target price on the stock in a research note on Friday, September 27th. Finally, Barclays decreased their target price on Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Certara presently has an average rating of "Hold" and an average target price of $15.92.

Certara Trading Down 1.1 %

Shares of NASDAQ CERT traded down $0.11 during mid-day trading on Tuesday, reaching $9.88. 854,891 shares of the company's stock were exchanged, compared to its average volume of 793,572. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -49.40, a PEG ratio of 5.04 and a beta of 1.51. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. Certara has a 52-week low of $9.72 and a 52-week high of $19.87. The company's 50-day moving average is $10.85 and its 200-day moving average is $13.33.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to analysts' expectations of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company's revenue was up 10.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.06 EPS.

Insider Buying and Selling at Certara

In other news, insider Patrick F. Smith sold 5,409 shares of the firm's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the sale, the insider now owns 50,091 shares of the company's stock, valued at approximately $552,503.73. This trade represents a 9.75 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Leif E. Pedersen sold 51,224 shares of the firm's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the sale, the insider now directly owns 99,704 shares in the company, valued at $1,125,658.16. This trade represents a 33.94 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Certara

Several hedge funds and other institutional investors have recently made changes to their positions in CERT. Blue Trust Inc. acquired a new stake in shares of Certara during the 2nd quarter worth about $26,000. Innealta Capital LLC purchased a new position in Certara during the 2nd quarter worth approximately $36,000. KBC Group NV grew its stake in Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company's stock worth $57,000 after buying an additional 1,584 shares during the last quarter. Intech Investment Management LLC purchased a new position in Certara during the 2nd quarter worth approximately $152,000. Finally, Algert Global LLC purchased a new position in Certara during the 2nd quarter worth approximately $156,000. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.